In light of the data published in recent years, PSMA PET/CT has been recommended by the EAU as being more appropriate in N-staging compared to MRI, abdominal contrast-enhanced CT or choline PET/CT, and it may be considered as an alternative to conventional imaging in the initial staging of high-risk PCa patients, but to date no outcome data exist to inform subsequent management [65]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.